Health Affairs, 25, no. 5 (2006): 1363-1370 doi: 10.1377/hlthaff.25.5.1363 © 2006 by Project HOPE	New Online   New Issue: China & India   Obesity In China   Pay Cuts For Medicare Docs   Access To Care Woes

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Simon, F. Search for Related Content PubMed PubMed Citation Articles by Simon, F. Related Collections Insurance Market Access To Care Business Of Health Consumer Issues Insurance Coverage International Issues Pharmaceuticals Research And Technology Health Spending

Health Tracking

MARKETWATCH

Market Access For Biopharmaceuticals: New Challenges

Biotechnology firms face new challenges as biologics account for an increasing share of product approvals and pipelines and their high costs are under scrutiny by regulators, employers, and consumers. Although the first generation of biologics often targeted niche markets with little impact on payers’ total costs, the current product wave addresses larger populations. To meet the needs of all stakeholders, manufacturers must adopt an evidence-based approach including three principles: demonstration of clinical and economic value, price evolution according to market conditions (from orphan diseases to large areas such as diabetes), and an early timetable integrating clinical and economic endpoints.

                      What's this?

This article has been cited by other articles:

				D. M. Dudzinski and A. S. Kesselheim Scientific and Legal Viability of Follow-on Protein Drugs N. Engl. J. Med., February 21, 2008; 358(8): 843 - 849. [Full Text] [PDF]